Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets

Journal of Immunology

Volumn 190, Issue 9, 2013, Pages 4595-4607

  Nimmagadda, Vamshi K ^a,b,c   Bever, Christopher T ^a,b,c   Vattikunta, Narasimha R ^c   Talat, Saifi ^c   Ahmad, Vakas ^c   Nagalla, Naveen K ^c   Trisler, David ^a,b,c   Judge, Susan I V ^a,b,c   Royal III, Walter ^a,b,c   Chandrasekaran, Krish ^a,c   Russell, James W ^a,c   Makar, Tapas K ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VA Multiple Sclerosis Center of Excellence East   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLYCEROL 3 PHOSPHATE DEHYDROGENASE (NAD); MYELIN OLIGODENDROCYTE GLYCOPROTEIN; SIRTUIN 1;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AXONAL INJURY; CELL LOSS; CONTROLLED STUDY; DEMYELINATION; DISEASE ASSOCIATION; DISEASE SEVERITY; IMMUNOMODULATION; MOLECULAR DYNAMICS; MOUSE; MYELITIS; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; WILD TYPE;

ANIMALS; APOPTOSIS; AXONS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INFLAMMATION; MICE; MICE, INBRED C57BL; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NAD; NEURONS; NEUROPROTECTIVE AGENTS; SIRTUIN 1; SPINAL CORD; STILBENES;

EID: 84876789195     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202584     Document Type: Article

References (78)

1. Noseworthy, J. H., C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker. 2000. Multiple sclerosis. N. Engl. J. Med. 343: 938-952.
2. Losseff, N. A., S. L. Webb, J. I. O'Riordan, R. Page, L. Wang, G. J. Barker, P. S. Tofts, W. I. McDonald, D. H. Miller, and A. J. Thompson. 1996. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119: 701-708. (Pubitemid 26237169)
3. Trapp, B. D., J. Peterson, R. M. Ransohoff, R. Rudick, S. Mörk, and L. Bö. 1998. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338: 278-285. (Pubitemid 28065253)
4. Fisher, J. B., D. A. Jacobs, C. E. Markowitz, S. L. Galetta, N. J. Volpe, M. L. Nano-Schiavi, M. L. Baier, E. M. Frohman, H. Winslow, T. C. Frohman, et al. 2006. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113: 324-332. (Pubitemid 43170783)
5. Gold, R., C. Linington, and H. Lassmann. 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953-1971. (Pubitemid 44289062)
6. Hohlfeld, R., and H. Wekerle. 2001. Immunological update on multiple sclerosis. Curr. Opin. Neurol. 14: 299-304. (Pubitemid 32510592)
7. Sawcer, S., G. Hellenthal, M. Pirinen, C. C. Spencer, N. A. Patsopoulos, L. Moutsianas, A. Dilthey, Z. Su, C. Freeman, S. E. Hunt, et al; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
8. Weiner, H. L., D. A. Hafler, R. J. Fallis, D. Johnson, K. A. Ault, and S. L. Hauser. 1984. T cell subsets in patients with multiple sclerosis. An overview. Ann. N. Y. Acad. Sci. 436: 281-293.
9. Lock, C., G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren, A. Langer-Gould, S. Strober, B. Cannella, J. Allard, et al. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8: 500-508. (Pubitemid 34546753)
10. Gran, B., G. X. Zhang, and A. Rostami. 2004. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory de-myelination. Crit. Rev. Immunol. 24: 111-128. (Pubitemid 39655089)
11. Berer, K., H. Wekerle, and G. Krishnamoorthy. 2011. B cells in spontaneous autoimmune diseases of the central nervous system. Mol. Immunol. 48: 1332-1337.
12. El-behi, M., A. Rostami, and B. Ciric. 2010. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J. Neuroimmune Pharmacol. 5: 189-197.
13. Lovett-Racke, A. E., Y. Yang, and M. K. Racke. 2011. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim. Biophys. Acta 1812: 246-251.
14. Hagemeier, K., W. Brück, and T. Kuhlmann. 2012. Multiple sclerosis-remye-lination failure as a cause of disease progression. Histol. Histopathol. 27: 277-287.
15. Johnson, K. P., B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, R. B. Schiffer, et al. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45: 1268-1276.
16. Jacobs, L. D., D. L. Cookfair, R. A. Rudick, R. M. Herndon, J. R. Richert, A. M. Salazar, J. S. Fischer, D. E. Goodkin, C. V. Granger, J. H. Simon, et al; 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.;The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39: 285-294. (Pubitemid 26100751)
17. Hickman, S. J., R. Kapoor, S. J. Jones, D. R. Altmann, G. T. Plant, and D. H. Miller. 2003. Corticosteroids do not prevent optic nerve atrophy following optic neuritis. J. Neurol. Neurosurg. Psychiatry 74: 1139-1141.
18. Parry, A., R. Corkill, A. M. Blamire, J. Palace, S. Narayanan, D. Arnold, P. Styles, and P. M. Matthews. 2003. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J. Neurol. 250: 171-178. (Pubitemid 36223091)
19. Imai, S., C. M. Armstrong, M. Kaeberlein, and L. Guarente. 2000. Transcrip-tional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795-800. (Pubitemid 30111843)
20. Guarente, L. 2000. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 14: 1021-1026. (Pubitemid 30324417)
21. Tissenbaum, H. A., and L. Guarente. 2001. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410: 227-230. (Pubitemid 32216597)
22. Rogina, B., and S. L. Helfand. 2004. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl. Acad. Sci. USA 101: 15998-16003. (Pubitemid 39507916)
23. Pallàs, M., J. G. Pizarro, J. Gutierrez-Cuesta, N. Crespo-Biel, D. Alvira, M. Tajes, M. Yeste-Velasco, J. Folch, A. M. Canudas, F. X. Sureda, et al. 2008. Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience 154: 1388-1397.
24. Kim, D., M. D. Nguyen, M. M. Dobbin, A. Fischer, F. Sananbenesi, J. T. Rodgers, I. Delalle, J. A. Baur, G. Sui, S. M. Armour, et al. 2007. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26: 3169-3179. (Pubitemid 47057498)
25. Qin, W., T. Yang, L. Ho, Z. Zhao, J. Wang, L. Chen, W. Zhao, M. Thiyagarajan, D. MacGrogan, J. T. Rodgers, et al. 2006. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropa-thology by calorie restriction. J. Biol. Chem. 281: 21745-21754. (Pubitemid 44181878)
26. Shindler, K. S., E. Ventura, T. S. Rex, P. Elliott, and A. Rostami. 2007. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest. Oph-thalmol. Vis. Sci. 48: 3602-3609. (Pubitemid 351261095)
27. Shindler, K. S., E. Ventura, M. Dutt, P. Elliott, D. C. Fitzgerald, and A. Rostami. 2010. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J. Neuroophthalmol. 30: 328-339.
28. Shindler, K. S., K. Revere, M. Dutt, G. S. Ying, and D. C. Chung. 2012. In vivo detection of experimental optic neuritis by pupillometry. Exp. Eye Res. 100: 1-6.
29. Mayford, M., M. E. Bach, Y. Y. Huang, L. Wang, R. D. Hawkins, and E. R. Kandel. 1996. Control of memory formation through regulated expression of a CaMKII transgene. Science. 274(5293): 1678-1683. (Pubitemid 26414891)
30. Makar, T. K., D. Trisler, C. T. Bever, J. E. Goolsby, K. T. Sura, S. Balasubramanian, S. Sultana, N. Patel, D. Ford, I. S. Singh, et al. 2008. Stem cell based delivery of IFN-beta reduces relapses in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 196: 67-81.
31. Makar, T. K., C. T. Bever, I. S. Singh, W. Royal, S. N. Sahu, T. P. Sura, S. Sultana, K. T. Sura, N. Patel, S. Dhib-Jalbut, and D. Trisler. 2009. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J. Neuroimmunol. 210: 40-51.
32. Makar, T. K., V. K. Nimmagadda, G. K. Patibandla, T. Le, S. I. Judge, D. Trisler, and C. T. Bever. 2012. Use of engineered bone marrow stem cells to deliver brain derived neurotrophic factor under the control of a tetracycline sensitive response element in experimental allergic encephalomyelitis. J. Neuroimmunol. 252: 1-15.
33. Quinn, T. A., M. Dutt, and K. S. Shindler. 2011. Optic neuritis and retinal ganglion cell loss in a chronic murine model of multiple sclerosis. Front Neurol 2: 50.
34. Singh, N. P., V. L. Hegde, L. J. Hofseth, M. Nagarkatti, and P. Nagarkatti. 2007. Resveratrol (trans-3, 5, 49-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol. Pharmacol. 72: 1508-1521. (Pubitemid 350146088)
35. Yang, J. S., L. Y. Xu, B. G. Xiao, G. Hedlund, and H. Link. 2004. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune en-cephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 156: 3-9. (Pubitemid 39310510)
36. Brunmark, C. A., A. Runström, L. Ohlsson, B. Sparre, T. Brodin, M. Aström, and G. Hedlund. 2002. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 130: 163-172. (Pubitemid 35240003)
37. Wegner, C., C. Stadelmann, R. Pförtner, E. Raymond, S. Feigelson, R. Alon, B. Timan, L. Hayardeny, and W. Brück. 2010. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalo-myelitis. J. Neuroimmunol. 227: 133-143.
38. Tolcos, M., E. Bateman, R. O'Dowd, R. Markwick, K. Vrijsen, A. Rehn, and S. Rees. 2011. Intrauterine growth restriction affects the maturation of myelin. Exp. Neurol. 232: 53-65.
39. Davis, H., X. Guo, S. Lambert, M. Stancescu, and J. J. Hickman. 2012. Small Molecule Induction of Human Umbilical Stem Cells into MBP-positive Oligo-dendrocytes in a Defined Three-Dimensional Environment. ACS Chem Neurosci 3: 31-39.
40. Tanno, M., J. Sakamoto, T. Miura, K. Shimamoto, and Y. Horio. 2007. Nucle-ocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J. Biol. Chem. 282: 6823-6832. (Pubitemid 47100909)
41. Li, Y., W. Xu, M. W. McBurney, and V. D. Longo. 2008. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab. 8: 38-48. (Pubitemid 351859225)
42. Revollo, J. R., A. A. Grimm, and S. Imai. 2004. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279: 50754-50763. (Pubitemid 40017813)
43. Linker, R. A., D. H. Lee, S. Demir, S. Wiese, N. Kruse, I. Siglienti, E. Gerhardt, H. Neumann, M. Sendtner, F. Lühder, and R. Gold. 2010. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 133: 2248-2263.
44. Michael, G. J., S. Averill, A. Nitkunan, M. Rattray, D. L. Bennett, Q. Yan, and J. V. Priestley. 1997. Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J. Neurosci. 17: 8476-8490. (Pubitemid 27461069)
45. Janardhan, V., and R. Bakshi. 2002. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J. Neurol. Sci. 205: 51-58. (Pubitemid 36158993)
46. Mostert, J. P., F. Admiraal-Behloul, J. M. Hoogduin, J. Luyendijk, D. J. Heersema, M. A. van Buchem, and J. De Keyser. 2008. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J. Neurol. Neurosurg. Psychiatry 79: 1027-1031.
47. Kerns, D., G. S. Vong, K. Barley, S. Dracheva, P. Katsel, P. Casaccia, V. Haroutunian, and W. Byne. 2010. Gene expression abnormalities and oligo-dendrocyte deficits in the internal capsule in schizophrenia. Schizophr. Res. 120: 150-158.
48. Aston, C., L. Jiang, and B. P. Sokolov. 2005. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol. Psychiatry 10: 309-322. (Pubitemid 40432684)
49. Konradi, C., S. E. Sillivan, and H. B. Clay. 2012. Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiol. Dis. 45: 37-47.
50. Kong, S., M. W. McBurney, and D. Fang. 2012. Sirtuin 1 in immune regulation and autoimmunity. Immunol. Cell Biol. 90: 6-13.
51. Li, P., Y. Zhao, X. Wu, M. Xia, M. Fang, Y. Iwasaki, J. Sha, Q. Chen, Y. Xu, and A. Shen. 2012. Interferon gamma (IFN-g) disrupts energy expenditure and metabolic homeostasis by suppressing SIRT1 transcription. Nucleic Acids Res. 40: 1609-1620.
52. Park, Y. D., Y. S. Kim, Y. M. Jung, S. I. Lee, Y. M. Lee, J. B. Bang, E. C. Kim. 2012. Porphyromonas gingivalis lipopolysaccharide regulates interleukin (IL)-17 and IL-23 expression via SIRT1 modulation in human periodontal ligament cells. Cytokine. 60: 284-293.
53. Kim, S. R., K. S. Lee, S. J. Park, K. H. Min, Y. H. Choe, H. Moon, W. H. Yoo, H. J. Chae, M. K. Han, and Y. C. Lee. 2010. Involvement of sirtuin 1 in airway inflammation and hyperresponsiveness of allergic airway disease. J. Allergy Clin. Immunol. 125: 449-460.e14.
54. Yeung, F., J. E. Hoberg, C. S. Ramsey, M. D. Keller, D. R. Jones, R. A. Frye, and M. W. Mayo. 2004. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23: 2369-2380. (Pubitemid 38954844)
55. Yang, S.-R., J. Wright, M. Bauter, K. Seweryniak, A. Kode, and I. Rahman. 2007. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am. J. Physiol. Lung Cell. Mol. Physiol. 292: L567-L576.
56. Gao, Z., and J. Ye. 2008. Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem. Biophys. Res. Commun. 376: 793-796.
57. Rajendrasozhan, S., S. R. Yang, V. L. Kinnula, and I. Rahman. 2008. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177: 861-870. (Pubitemid 351600664)
58. Yoshizaki, T., J. C. Milne, T. Imamura, S. Schenk, N. Sonoda, J. L. Babendure, J.-C. Lu, J. J. Smith, M. R. Jirousek, and J. M. Olefsky. 2009. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol. Cell. Biol. 29: 1363-1374.
59. Legutko, A., T. Marichal, L. Fiévez, D. Bedoret, A. Mayer, H. de Vries, L. Klotz, P. V. Drion, C. Heirman, D. Cataldo, et al. 2011. Sirtuin 1 promotes Th2 responses and airway allergy by repressing peroxisome proliferator-activated receptor-g activity in dendritic cells. J. Immunol. 187: 4517-4529.
60. Budde, M. D., J. H. Kim, H.-F. Liang, J. H. Russell, A. H. Cross, and S.-K. Song. 2008. Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis. NMR Biomed. 21: 589-597.
61. Budde, M. D., M. Xie, A. H. Cross, and S. K. Song. 2009. Axial diffusivity is the primary correlate of axonal injury in the experimental autoimmune encephalo-myelitis spinal cord: a quantitative pixelwise analysis. J. Neurosci. 29: 2805-2813.
62. Dandekar, A. A., G. F. Wu, L. Pewe, and S. Perlman. 2001. Axonal damage is T cell mediated and occurs concomitantly with demyelination in mice infected with a neurotropic coronavirus. J. Virol. 75: 6115-6120. (Pubitemid 32553142)
63. Lee, V. M., M. J. Carden, W. W. Schlaepfer, and J. Q. Trojanowski. 1987. Monoclonal antibodies distinguish several differentially phosphorylated states of the two largest rat neurofilament subunits (NF-H and NF-M) and demonstrate their existence in the normal nervous system of adult rats. J. Neurosci. 7: 3474-3488. (Pubitemid 18000675)
64. Linker, R. A., M. Mäurer, S. Gaupp, R. Martini, B. Holtmann, R. Giess, P. Rieckmann, H. Lassmann, K. V. Toyka, M. Sendtner, and R. Gold. 2002. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. 8: 620-624. (Pubitemid 34633441)
65. Luo, J., A. Y. Nikolaev, S. Imai, D. Chen, F. Su, A. Shiloh, L. Guarente, and W. Gu. 2001. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148. (Pubitemid 33035941)
66. Vaziri, H., S. K. Dessain, E. Ng Eaton, S. I. Imai, R. A. Frye, T. K. Pandita, L. Guarente, and R. A. Weinberg. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159. (Pubitemid 33035942)
67. Cohen, H. Y., C. Miller, K. J. Bitterman, N. R. Wall, B. Hekking, B. Kessler, K. T. Howitz, M. Gorospe, R. de Cabo, and D. A. Sinclair. 2004. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305: 390-392. (Pubitemid 38938153)
68. Brunet, A., L. B. Sweeney, J. F. Sturgill, K. F. Chua, P. L. Greer, Y. Lin, H. Tran, S. E. Ross, R. Mostoslavsky, H. Y. Cohen, et al. 2004. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011-2015. (Pubitemid 38393275)
69. Chen, J., Y. Zhou, S. Mueller-Steiner, L. F. Chen, H. Kwon, S. Yi, L. Mucke, and L. Gan. 2005. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem. 280: 40364-40374. (Pubitemid 41779174)
70. Makar, T. K., D. Trisler, T. K. Sura, S. Sultana, N. Patel, C. T. Bever. 2008. Brain derived neurotrophic factor treatment reduces inflammation and apoptosis in experimental allergic encephalomyelitis. J. Neurol. Sci. 15: 70-76.
71. Uchida, K., H. Nakajima, T. Hirai, T. Yayama, K. Chen, A. R. Guerrero, W. E. Johnson, and H. Baba. 2012. The retrograde delivery of adenovirus vector carrying the gene for brain-derived neurotrophic factor protects neurons and oligodendrocytes from apoptosis in the chronically compressed spinal cord of twy/twy mice. Spine 37: 2125-2135.
72. Steinkamp, M., N. Schulte, U. Spaniol, C. Pflüger, C. Hartmann, J. Kirsch, and G. B. von Boyen. 2012. Brain derived neurotrophic factor inhibits apoptosis in enteric glia during gut inflammation. Med. Sci. Monit. 18: BR117-BR122.
73. Zocchi, L., and P. Sassone-Corsi. 2012. SIRT1-mediated deacetylation of MeCP2 contributes to BDNF expression. Epigenetics 7: 695-700.
74. Jeong, H., D. E. Cohen, L. Cui, A. Supinski, J. N. Savas, J. R. Mazzulli, J. R. Yates, III, L. Bordone, L. Guarente, and D. Krainc. 2012. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat. Med. 18: 159-165.
75. Jiang, M., J. Wang, J. Fu, L. Du, H. Jeong, T. West, L. Xiang, Q. Peng, Z. Hou, H. Cai, et al. 2012. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat. Med. 18: 153-158.
76. Lee, D. H., E. Geyer, A. C. Flach, K. Jung, R. Gold, A. Flügel, R. A. Linker, and F. L ühder. 2012. Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol. 123: 247-258.
77. Chang, J., B. Zhang, H. Heath, N. Galjart, X. Wang, and J. Milbrandt. 2010. Nicotinamide adenine dinucleotide (NAD)-regulated DNA methylation alters CCCTC-binding factor (CTCF)/cohesin binding and transcription at the BDNF locus. Proc. Natl. Acad. Sci. USA 107: 21836-21841.
78. Wang, P., T. Y. Xu, Y. F. Guan, W. W. Tian, B. Viollet, Y. C. Rui, Q. W. Zhai, D. F. Su, and C. Y. Miao. 2011. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann. Neurol. 69: 360-374.